Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology
Scientific Pioneers, Industry Veterans Advance Company toward IND Filing CAMBRIDGE, Mass.—November 18, 2014—Intellia Therapeutics, a new company formed to develop therapeutic products using CRISPR-Cas9 technology for gene editing and repair, announced today that it has closed a Series A investment
